Panagora Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Panagora Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-574,225	Closed	-$1.16M	–	1631
2022 Q1	$1.16M	Buy	574,225 +18,000	+3%	+$35.4K	0.01%	871
2021 Q4	$1.51M	Buy	556,225 +76,286	+16%	+$282K	0.01%	750
2021 Q3	$2.14M	Buy	479,939 +42,720	+10%	+$206K	0.01%	664
2021 Q2	$2.54M	Sell	437,219 -19,024	-4%	-$111K	0.01%	641
2021 Q1	$3.2M	Sell	456,243 -15,688	-3%	-$105K	0.02%	590
2020 Q4	$2.27M	Buy	471,931 +107,919	+30%	+$546K	0.01%	664
2020 Q3	$2.12M	Buy	364,012 +88,206	+32%	+$528K	0.01%	617
2020 Q2	$1.86M	Buy	275,806 +227,375	+469%	+$1.72M	0.01%	702
2020 Q1	$308K	Sell	48,431 -4,502	-9%	-$36.1K	﹤0.01%	1316
2019 Q4	$552K	Sell	52,933 -261,095	-83%	-$1.9M	﹤0.01%	1271
2019 Q3	$1.23M	Buy	314,028 +288,064	+1,109%	+$2.33M	0.01%	939
2019 Q2	$386K	Buy	25,964 +25,860	+24,865%	+$467K	﹤0.01%	1524
2019 Q1	$3K	Hold	104	–	–	﹤0.01%	2446
2018 Q4	$2K	Sell	104 -1,964	-95%	-$40.1K	﹤0.01%	2407
2018 Q3	$61K	Hold	2,068	–	–	﹤0.01%	1984
2018 Q2	$94K	Hold	2,068	–	–	﹤0.01%	1865
2018 Q1	$109K	Sell	2,068 -10,195	-83%	-$595K	﹤0.01%	1833
2017 Q4	$834K	Sell	12,263 -596	-5%	-$41.7K	﹤0.01%	1204
2017 Q3	$1.06M	Sell	12,859 -90	-0.7%	-$7.13K	﹤0.01%	1092
2017 Q2	$1.21M	Buy	12,949 +12,845	+12,351%	+$786K	﹤0.01%	1041
2017 Q1	$7K	Hold	104	–	–	﹤0.01%	2285
2016 Q4	$5K	Hold	104	–	–	﹤0.01%	2316
2016 Q3	$4K	Buy	+104	New	+$2.23K	﹤0.01%	2375
2016 Q1	–	Sell	-2,517	Closed	-$88K	–	2357
2015 Q4	$88K	Buy	+2,517	New	+$162K	﹤0.01%	1829
2015 Q3	–	Sell	-112	Closed	-$10K	–	2461
2015 Q2	$10K	Sell	112 -2,203	-95%	-$189K	﹤0.01%	2365
2015 Q1	$172K	Sell	2,315 -2,489	-52%	-$176K	﹤0.01%	1733
2014 Q4	$269K	Buy	4,804 +4,328	+909%	+$227K	﹤0.01%	1519
2014 Q3	$22K	Hold	476	–	–	﹤0.01%	2146
2014 Q2	$20K	Sell	476 -888	-65%	-$45.7K	﹤0.01%	2232
2014 Q1	$94K	Buy	+1,364	New	+$100K	﹤0.01%	1950
2013 Q3	–	Sell	-8,503	Closed	-$570K	–	2382
2013 Q2	$570K	Buy	+8,503	New	+$382K	﹤0.01%	1263

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Panagora Asset Management's CLVS Position: Q2 2022 in Review

Panagora Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 574,225 shares — an estimated $1.16M sold.

Panagora Asset Management first reported a position in CLVS in Q2 2013 and held it in 31 quarters. The position peaked at $3.2M in Q1 2021. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

Panagora Asset Management reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
Panagora Asset Management sold 574,225 Clovis Oncology, Inc. shares in Q2 2022, an estimated $1.16M.
Panagora Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 31 quarters.
Panagora Asset Management's Clovis Oncology, Inc. position peaked at $3.2M in Q1 2021.
115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Panagora Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.